These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 14999194)

  • 21. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
    Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction.
    Gruberg L; Suleiman M; Kapeliovich M; Hammerman H; Grenadier E; Boulus M; Amikam S; Markiewicz W; Beyar R
    J Invasive Cardiol; 2006 Feb; 18(2):59-62. PubMed ID: 16446517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors and clopidogrel alone and in combination in non-ST-segment elevation myocardial infarction (from the National Registry of Myocardial Infarction-4).
    Bromberg-Marin G; Marin-Neto JA; Parsons LS; Canto JG; Rogers WJ;
    Am J Cardiol; 2006 Nov; 98(9):1125-31. PubMed ID: 17056312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
    Marso SP; Lincoff AM; Ellis SG; Bhatt DL; Tanguay JF; Kleiman NS; Hammoud T; Booth JE; Sapp SK; Topol EJ
    Circulation; 1999 Dec 21-28; 100(25):2477-84. PubMed ID: 10604884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization: Pooled analysis from EPIC, EPILOG, and EPISTENT.
    Cho L; Bhatt DL; Wolski K; Lincoff M; Topol EJ; Moliterno DJ
    Am Heart J; 2001 Apr; 141(4):599-602. PubMed ID: 11275926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
    Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three-year duration of benefit from abciximab in patients receiving stents for acute myocardial infarction in the randomized double-blind ADMIRAL study.
    Admiral Investigators
    Eur Heart J; 2005 Dec; 26(23):2520-3. PubMed ID: 16249219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction.
    Gum PA; Lincoff AM
    Int J Clin Pract; 2003; 57(1):43-8. PubMed ID: 12587942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T; McGavin JK; Goa KL
    Drugs; 2003; 63(11):1121-63. PubMed ID: 12749745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.
    De Luca G; Suryapranata H; Stone GW; Antoniucci D; Tcheng JE; Neumann FJ; Van de Werf F; Antman EM; Topol EJ
    JAMA; 2005 Apr; 293(14):1759-65. PubMed ID: 15827315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention.
    Labinaz M; Ho C; Banerjee S; Martin J; Chen S; Mensinkai S
    Can J Cardiol; 2007 Oct; 23(12):963-70. PubMed ID: 17932572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point.
    Ndrepepa G; Berger PB; Mehilli J; Seyfarth M; Neumann FJ; Schömig A; Kastrati A
    J Am Coll Cardiol; 2008 Feb; 51(7):690-7. PubMed ID: 18279731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial.
    Ellis SG; Armstrong P; Betriu A; Brodie B; Herrmann H; Montalescot G; Neumann FJ; Smith JJ; Topol E;
    Am Heart J; 2004 Apr; 147(4):E16. PubMed ID: 15077099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
    Kereiakes DJ; Berkowitz SD; Lincoff AM; Tcheng JE; Wolski K; Achenbach R; Melsheimer R; Anderson K; Califf RM; Topol EJ
    Am Heart J; 2000 Jul; 140(1):74-80. PubMed ID: 10874266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.
    Berger PB; Best PJ; Topol EJ; White J; DiBattiste PM; Chan AW; Kristensen SD; Herrmann HC; Moliterno DJ
    Am Heart J; 2005 May; 149(5):869-75. PubMed ID: 15894970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines.
    Winchester DE; Wen X; Brearley WD; Park KE; Anderson RD; Bavry AA
    J Am Coll Cardiol; 2011 Mar; 57(10):1190-9. PubMed ID: 21371635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of abciximab on prognosis in diabetic patients undergoing primary percutaneous coronary intervention.
    Perkan A; Vitrella G; Barbati G; De Monte A; D'Agata B; Merlo M; Giannini F; Della Grazia E; Rakar S; Salvi A; Igidbashian D; Morgera T; Zalukar W; Sinagra G
    J Cardiovasc Med (Hagerstown); 2013 Feb; 14(2):127-35. PubMed ID: 22343257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.